Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Silo Pharma, Inc. (SILO)

Silo Pharma sells shares and pre-funded warrants in private placement for about $815,000 net

Negative Impact 2 of 5 financing

Silo Pharma, Inc. entered into securities purchase agreements on November 5, 2026, and closed a private placement with accredited investors on November 6, 2026. The company expects net proceeds of approximately $815,000 for working capital and general corporate purposes, and it agreed to register the resale of the shares and warrant shares with the SEC, which adds potential future share supply for existing shareholders.

Key points

  • Sold 136,005 shares of common stock at $1.50 per share
  • Issued pre-funded warrants for up to 430,661 shares of common stock at $1.4999 per warrant
  • Expected net proceeds of approximately $815,000 after placement agent fees and offering expenses
  • Must file a resale registration statement within 30 days of the November 5, 2026 registration rights agreement, with effectiveness targeted within 60 days (90 days if the SEC conducts a full review)

The filing

CompanySilo Pharma, Inc. (SILO)
Form8-K, current report
Filed with the SECNov 6, 2026, 5:08 PM ET
Accession number0001213900-26-116982

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.